MedTrace Logo

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

NCT05001373 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-05-01

No results posted yet for this study

Summary

A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health

Conditions

Interventions

BIOLOGICAL

Core-g28v2 60mer mRNA Vaccine

100µg, Intramuscularly

BIOLOGICAL

eOD-GT8 60mer mRNA Vaccine

100µg, Intramuscularly

Sponsors & Collaborators

  • ModernaTX, Inc.

    collaborator INDUSTRY

  • George Washington University

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • UT Health San Antonio

    collaborator UNKNOWN

  • International AIDS Vaccine Initiative

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-12
Primary Completion
2023-06-20
Completion
2024-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001373 on ClinicalTrials.gov